Potential Strategy Against Blood Glucose Drops in Type 1 Diabetes Sep. 30, 2024 — Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

Pasireotide, a new panreceptor analog, might control clinical symptoms and hormone release in patients resistant to standard somatostatin analog therapy. mTOR and tyrosine kinase inhibitors may ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Long-acting growth hormone Treatment of adults with growth hormone deficiency. Supplemental BLA accepted for review Paltusotine (Crinetics Pharmaceuticals) Somatostatin receptor type 2 agonist ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

If the excess growth hormone secretion occurs before the fusion of the epiphyseal ... remission after surgery or who are unsuitable for surgery. These include as somatostatin-receptor ligands (SRL) ...

In one study, for example, Swaab and his colleagues found that in one region of the brain, transgender women, like other women, have fewer cells associated with the regulator hormone somatostatin ...